Disease: progressive non-small cell lung cancer ×
Source: ALL
Disease Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
progressive non-small cell lung cancer
CUI: C4733576
Disease: progressive non-small cell lung cancer
0.010 GeneticVariation BEFREE Osimertinib has been approved by the Food and Drug Administration (FDA) of the United States (US) for the treatment of progressive non-small cell lung cancer (NSCLC) that has acquired T790M mutation during treatment with first-line epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). 31802642 2019